


PRODUCT INFORMATION



Teneligliptin (hydrobromide hydrate)

Item No. 29515

CAS Registry No.: 1572583-29-9
Formal Name: [(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-1-piperazinyl]-2-pyrrolidinyl]-3-thiazolidinyl-methanone, hydrobromide hydrate
MF: C₂₂H₃₀N₆OS • 2.5HBr [XH₂O]
FW: 426.6
Purity: ≥98%
UV/Vis.: λ_{max}: 246 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Teneligliptin (hydrobromide hydrate) is supplied as a crystalline solid. A stock solution may be made by dissolving the teneligliptin (hydrobromide hydrate) in the solvent of choice, which should be purged with an inert gas. Teneligliptin (hydrobromide hydrate) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of teneligliptin (hydrobromide hydrate) in ethanol is approximately 2 mg/ml and approximately 30 mg/ml in DMSO and DMF.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of teneligliptin (hydrobromide hydrate) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of teneligliptin (hydrobromide hydrate) in PBS, pH 7.2, is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Teneligliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor (IC₅₀s = 0.37 and 0.29 nM for the human and rat enzymes, respectively).¹ It is selective for DPP-4 over DPP-8 and DPP-9 (IC₅₀s = 260 and 540 nM, respectively, for the human enzymes). Teneligliptin (0.03-1 mg/kg) inhibits increases in plasma glucose levels in an oral glucose tolerance test in Zucker fatty rats. It reduces body weight, inhibits hepatic steatosis, and decreases plasma insulin levels in a mouse model of high-fat diet-induced obesity when administered at doses of 30 and 60 mg/kg.² Teneligliptin scavenges hydroxyl radicals in a cell-free assay (IC₅₀ = 0.315 mM) and decreases urinary levels of 8-hydroxy-2'-deoxyguanosine (8-OHdG; Item No. 89320), a marker of oxidative stress, in a DPP-4-deficient rat model of diabetes induced by streptozotocin (STZ; Item No. 13104) when administered at a dose of 10 mg/kg per day.³

References

1. Yoshida, T., Akahoshi, F., Sakashita, H., *et al. Bioorg. Med. Chem.* **20(19)**, 5705-5719 (2012).
2. Fukuda-Tsuru, S., Kakimoto, T., Utsumi, H., *et al. Eur. J. Pharmacol.* **723**, 207-215 (2014).
3. Kimura, S., Inoguchi, T., Yamasaki, T., *et al. Metabolism* **65(3)**, 138-145 (2016).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/16/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM